Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

Performance of electrocardiographic criteria for left ventricular hypertrophy as compared with cardiac computed tomography: from the Rule Out Myocardial Infarction Using Computer Assisted Tomography trial. J Hypertens (2010) 0.89

Current challenges in the clinical management of hypertension. Nat Rev Cardiol (2011) 0.89

Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther (2010) 0.84

Functional polymorphisms in genes of the Angiotensin and Serotonin systems and risk of hypertrophic cardiomyopathy: AT1R as a potential modifier. J Transl Med (2010) 0.84

Arginine vasopressin receptor signaling and functional outcomes in heart failure. Cell Signal (2015) 0.82

Hypertension: Cardiac hypertrophy as a target of antihypertensive therapy. Nat Rev Cardiol (2010) 0.78

Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study. Nephrol Dial Transplant (2016) 0.78

Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging (2010) 0.77

Telmisartan and cardioprotection. Vasc Health Risk Manag (2011) 0.76

Impact of telmisartan in modifying vascular risk. Integr Blood Press Control (2010) 0.75

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09

Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17

Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet (2011) 13.10

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72

Point: cardiovascular variability is/is not an index of autonomic control of circulation. J Appl Physiol (1985) (2006) 11.52

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43

Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet (2004) 9.01

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J (2003) 8.51

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49

Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83

Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35

Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08

Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J (2005) 6.93

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA (2005) 6.68

Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 6.55

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J (2013) 6.17

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16

Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05

European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens (2003) 5.94

Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA (2003) 5.67

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47

Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010) 5.30

Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27

Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J (2013) 5.23

Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet (2004) 5.19

Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med (2006) 5.18

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 4.99

Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91